Past research indicated that CLDN18.2 was a good marker of poor survival in gastric cancer and that the downregulation of CLDN18 may represent an early event of gastric carcinogenesis with an intestinal phenotype (181, 182). This evidence concerns the gene CLDN18 and gastric cancer.